Cancer-related transcriptional targets of the circadian gene NPAS2 identified by genome-wide ChIP-on-chip analysis

Cancer Letters

Volumn 284, Issue 2, 2009, Pages 149-156

  Yi, Chun Hui ^a   Zheng, Tongzhang ^a   Leaderer, Derek ^a   Hoffman, Aaron ^a   Zhu, Yong ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ChIP on chip; NPAS2; Transcriptional targets

Indexed keywords

NEURONAL PAS DOMAIN PROTEIN 2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CARCINOGENESIS; CELL CYCLE; CELL STRAIN MCF 7; CONTROLLED STUDY; GENE IDENTIFICATION; GENE MAPPING; GENE TARGETING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TUMOR GENE;

ADENOCARCINOMA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN IMMUNOPRECIPITATION; CIRCADIAN RHYTHM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; NEOPLASM PROTEINS; NERVE TISSUE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC;

EID: 69549127974     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.04.017     Document Type: Article

References (37)

1. Vitaterna M.H., King D.P., Chang A.M., Kornhauser J.M., Lowrey P.L., McDonald J.D., Dove W.F., Pinto L.H., Turek F.W., and Takahashi J.S. Mutagenesis and mapping of a mouse gene, Clock, essential for circadian behavior. Science 264 (1994) 719-725
2. Bunger M.K., Wilsbacher L.D., Moran S.M., Clendenin C., Radcliffe L.A., Hogenesch J.B., Simon M.C., Takahashi J.S., and Bradfield C.A. Mop3 is an essential component of the master circadian pacemaker in mammals. Cell 103 (2000) 1009-1017
3. Dudley C.A., Erbel-Sieler C., Estill S.J., Reick M., Franken P., Pitts S., and McKnight S.L. Altered patterns of sleep and behavioral adaptability in NPAS2-deficient mice. Science 301 (2003) 379-383
4. Reick M., Garcia J.A., Dudley C., and McKnight S.L. NPAS2: an analog of clock operative in the mammalian forebrain. Science 293 (2001) 506-509
5. Zhu Y., Stevens R.G., Leaderer D., Hoffman A., Holford T., Zhang Y., Brown H.N., and Zheng T. Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk. Breast Cancer Res. Treat. 107 (2008) 421-425
6. Chu L.W., Zhu Y., Yu K., Zheng T., Yu H., Zhang Y., Sesterhenn I., Chokkalingam A.P., Danforth K.N., Shen M.C., Stanczyk F.Z., Gao Y.T., and Hsing A.W. Variants in circadian genes and prostate cancer risk: a population-based study in China. Prostate Cancer Prostatic Dis. (2007)
7. Zhu Y., Leaderer D., Guss C., Brown H.N., Zhang Y., Boyle P., Stevens R.G., Hoffman A., Qin Q., Han X., and Zheng T. Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma. Int. J. Cancer 120 (2007) 432-435
8. Fu L., Pelicano H., Liu J., Huang P., and Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111 (2002) 41-50
9. Hoffman A.E., Zheng T., Ba Y., and Zhu Y. The circadian gene NPAS2 a putative tumor suppressor is involved in DNA damage response. Mol. Cancer Res. 6 (2008) 1461-1468
10. Hughes T.R., Marton M.J., Jones A.R., Roberts C.J., Stoughton R., Armour C.D., Bennett H.A., Coffey E., Dai H., He Y.D., Kidd M.J., King A.M., Meyer M.R., Slade D., Lum P.Y., Stepaniants S.B., Shoemaker D.D., Gachotte D., Chakraburtty K., Simon J., Bard M., and Friend S.H. Functional discovery via a compendium of expression profiles. Cell 102 (2000) 109-126
11. Lee T.I., Rinaldi N.J., Robert F., Odom D.T., Bar-Joseph Z., Gerber G.K., Hannett N.M., Harbison C.T., Thompson C.M., Simon I., Zeitlinger J., Jennings E.G., Murray H.L., Gordon D.B., Ren B., Wyrick J.J., Tagne J.B., Volkert T.L., Fraenkel E., Gifford D.K., and Young R.A. Transcriptional regulatory networks in Saccharomyces cerevisiae. Science 298 (2002) 799-804
12. Reppert S.M., and Weaver D.R. Coordination of circadian timing in mammals. Nature 418 (2002) 935-941
13. Schibler U., and Sassone-Corsi P. A web of circadian pacemakers. Cell 111 (2002) 919-922
14. Yamamoto T., Nakahata Y., Soma H., Akashi M., Mamine T., and Takumi T. Transcriptional oscillation of canonical clock genes in mouse peripheral tissues. BMC Mol. Biol. 5 (2004) 18
15. Garcia-Tunon I., Ricote M., Ruiz A.A., Fraile B., Paniagua R., and Royuela M. Influence of IFN-gamma and its receptors in human breast cancer. BMC Cancer 7 (2007) 158
16. Kaul S.C., Hasan K., and Wadhwa R. CARF regulates p19ARF-p53-p21WAF1 senescence pathway by multiple checkpoints. Ann. NY Acad. Sci. 1067 (2006) 217-219
17. Kamrul H.M., Wadhwa R., and Kaul S.C. CARF binds to three members (ARF, p53, and HDM2) of the p53 tumor-suppressor pathway. Ann. NY Acad. Sci. 1100 (2007) 312-315
18. Jinno S., Suto K., Nagata A., Igarashi M., Kanaoka Y., Nojima H., and Okayama H. Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO. J. 13 (1994) 1549-1556
19. Saras J., Franzen P., Aspenstrom P., Hellman U., Gonez L.J., and Heldin C.H. A novel GTPase-activating protein for Rho interacts with a PDZ domain of the protein-tyrosine phosphatase PTPL1. J. Biol. Chem. 272 (1997) 24333-24338
20. Ripperger T., von Neuhoff N., Kamphues K., Emura M., Lehmann U., Tauscher M., Schraders M., Groenen P., Skawran B., Rudolph C., Callet-Bauchu E., van Krieken J.H., Schlegelberger B., and Steinemann D. Promoter methylation of PARG1, a novel candidate tumor suppressor gene in mantle-cell lymphomas. Haematologica 92 (2007) 460-468
21. Samady L., Dennis J., Budhram-Mahadeo V., and Latchman D.S. Activation of CDK4 gene expression in human breast cancer cells by the Brn-3b POU family transcription factor. Cancer Biol. Ther. 3 (2004) 317-323
22. Budhram-Mahadeo V.S., Irshad S., Bowen S., Lee S.A., Samady L., Tonini G.P., and Latchman D.S. Proliferation-associated Brn-3b transcription factor can activate cyclin D1 expression in neuroblastoma and breast cancer cells. Oncogene 27 (2008) 145-154
23. Kyriakis J.M., and Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81 (2001) 807-869
24. Regnauld K., Nguyen Q.D., Vakaet L., Bruyneel E., Launay J.M., Endo T., Mareel M., Gespach C., and Emami S. G-protein alpha(olf) subunit promotes cellular invasion, survival, and neuroendocrine differentiation in digestive and urogenital epithelial cells. Oncogene 21 (2002) 4020-4031
25. Yu Y.R., Fong A.M., Combadiere C., Gao J.L., Murphy P.M., and Patel D.D. Defective antitumor responses in CX3CR1-deficient mice. Int. J. Cancer 121 (2007) 316-322
26. Tang L., Hu H.D., Hu P., Lan Y.H., Peng M.L., Chen M., and Ren H. Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma. Gene Ther. 14 (2007) 1226-1234
27. Smith J.S., Tachibana I., Pohl U., Lee H.K., Thanarajasingam U., Portier B.P., Ueki K., Ramaswamy S., Billings S.J., Mohrenweiser H.W., Louis D.N., and Jenkins R.B. A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics 64 (2000) 44-50
28. Onda M., Li D., Suzuki S., Nakamura I., Takenoshita S., Brogren C.H., Stampanoni S., and Rampino N. Expansion of microsatellite in the thyroid hormone receptor-alpha1 gene linked to increased receptor expression and less aggressive thyroid cancer. Clin. Cancer Res. 8 (2002) 2870-2874
29. Silva J.M., Dominguez G., Gonzalez-Sancho J.M., Garcia J.M., Silva J., Garcia-Andrade C., Navarro A., Munoz A., and Bonilla F. Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene 21 (2002) 4307-4316
30. Seki Y., Suico M.A., Uto A., Hisatsune A., Shuto T., Isohama Y., and Kai H. The ETS transcription factor MEF is a candidate tumor suppressor gene on the X chromosome. Cancer Res. 62 (2002) 6579-6586
31. Liu Y., Hedvat C.V., Mao S., Zhu X.H., Yao J., Nguyen H., Koff A., and Nimer S.D. The ETS protein MEF is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCFSkp2. Mol. Cell Biol. 26 (2006) 3114-3123
32. Woelfle U., Cloos J., Sauter G., Riethdorf L., Janicke F., van Diest P., Brakenhoff R., and Pantel K. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res. 63 (2003) 5679-5684
33. Dallas P.B., Gottardo N.G., Firth M.J., Beesley A.H., Hoffmann K., Terry P.A., Freitas J.R., Boag J.M., Cummings A.J., and Kees U.R. Gene expression levels assessed by oligonucleotide microarray analysis and quantitative real-time RT-PCR -- how well do they correlate?. BMC Genom. 6 (2005) 59
34. Etienne W., Meyer M.H., Peppers J., and Meyer Jr. R.A. Comparison of mRNA gene expression by RT-PCR and DNA microarray. Biotechniques 36 (2004) 618-626
35. Li X., and Quigg R.J. An integrated strategy for the optimization of microarray data interpretation. Gene Exp. 12 (2005) 223-230
36. Storch K.F., Lipan O., Leykin I., Viswanathan N., Davis F.C., Wong W.H., and Weitz C.J. Extensive and divergent circadian gene expression in liver and heart. Nature 417 (2002) 78-83
37. Pham T.H., Clemente J.C., Satou K., and Ho T.B. Computational discovery of transcriptional regulatory rules. Bioinformatics 21 2 (2005) ii101-ii107